2018 AGDF Program - 67

OSPHOS® (clodronate injection)
Bisphosphonate
For use in horses only.
Brief Summary (For Full Prescribing Information, see package
insert)
CAUTION: Federal (USA) law restricts this drug to use by or on
the order of a licensed veterinarian.
DESCRIPTION: Clodronate disodium is a non-amino, chlorocontaining bisphosphonate. Chemically, clodronate disodium is
(dichloromethylene) diphosphonic acid disodium salt and is
manufactured from the tetrahydrate form.
INDICATION: For the control of clinical signs associated with
navicular syndrome in horses.
CONTRAINDICATIONS: Horses with hypersensitivity to clodronate
disodium should not receive OSPHOS.

controls the
clinical signs
associated
with

NAVICULAR
SYNDROME
Easily Administered
via intramuscular
injection

Well Tolerated*
in clinical trials

Proven Efficacy*
at 6 months post
treatment

No Reconstitution
Required

Learn more online

WARNINGS: Do not use in horses intended for human consumption.
HUMAN WARNINGS: Not for human use. Keep this and all drugs
out of the reach of children. Consult a physician in case of accidental human exposure.
PRECAUTIONS: As a class, bisphosphonates may be associated with gastrointestinal and renal toxicity. Sensitivity to drug
associated adverse reactions varies with the individual patient.
Renal and gastrointestinal adverse reactions may be associated
with plasma concentrations of the drug. Bisphosphonates are
excreted by the kidney; therefore, conditions causing renal impairment may increase plasma bisphosphonate concentrations
resulting in an increased risk for adverse reactions. Concurrent
administration of other potentially nephrotoxic drugs should be
approached with caution and renal function should be monitored. Use of bisphosphonates in patients with conditions or
diseases affecting renal function is not recommended.
Administration of bisphosphonates has been associated
with abdominal pain (colic), discomfort, and agitation in horses.
Clinical signs usually occur shortly after drug administration and
may be associated with alterations in intestinal motility. In horses
treated with OSPHOS these clinical signs usually began within
2 hours of treatment. Horses should be monitored for at least 2
hours following administration of OSPHOS.
Bisphosphonates affect plasma concentrations of some minerals and electrolytes such as calcium, magnesium and potassium, immediately post-treatment, with effects lasting up
to several hours. Caution should be used when administering
bisphosphonates to horses with conditions affecting mineral or
electrolyte homeostasis (e.g. hyperkalemic periodic paralysis,
hypocalcemia, etc.).
The safe use of OSPHOS has not been evaluated in horses less
than 4 years of age. The effect of bisphosphonates on the skeleton of growing horses has not been studied; however, bisphosphonates inhibit osteoclast activity which impacts bone turnover
and may affect bone growth.
Bisphosphonates should not be used in pregnant or lactating
mares, or mares intended for breeding. The safe use of OSPHOS
has not been evaluated in breeding horses or pregnant or lactating mares. Bisphosphonates are incorporated into the bone
matrix, from where they are gradually released over periods of
months to years. The extent of bisphosphonate incorporation
into adult bone, and hence, the amount available for release
back into the systemic circulation, is directly related to the total dose and duration of bisphosphonate use. Bisphosphonates
have been shown to cause fetal developmental abnormalities
in laboratory animals. The uptake of bisphosphonates into fetal
bone may be greater than into maternal bone creating a possible
risk for skeletal or other abnormalities in the fetus. Many drugs,
including bisphosphonates, may be excreted in milk and may be
absorbed by nursing animals.
Increased bone fragility has been observed in animals treated
with bisphosphonates at high doses or for long periods of time.
Bisphosphonates inhibit bone resorption and decrease bone
turnover which may lead to an inability to repair micro damage
within the bone. In humans, atypical femur fractures have been
reported in patients on long term bisphosphonate therapy; however, a causal relationship has not been established.
ADVERSE REACTIONS: The most common adverse reactions
reported in the field study were clinical signs of discomfort or
nervousness, colic and/or pawing. Other signs reported were
lip licking, yawning, head shaking, injection site swelling, and
hives/pruritus.

www.dechra-us.com
www.osphos.com

As with all drugs, side effects may occur. In field studies, the most common side effects reported were signs of discomfort or
nervousness, colic, and/or pawing. OSPHOS should not be used in pregnant or lactating mares, or mares intended for breeding.
Use of OSPHOS in patients with conditions affecting renal function or mineral or electrolyte homeostasis is not recommended.
Refer to the prescribing information for complete details or visit www.dechra-us.com or call 866.933.2472.

CAUTION: Federal law restricts this drug to use by or on the order of licensed veterinarian.
* Freedom of Information Summary, Original New Animal Drug Application, NADA 141-427, for OSPHOS. April 28, 2014.
Dechra Veterinary Products US and the Dechra D logo are registered trademarks of Dechra Pharmaceuticals PLC. © 2016 Dechra Ltd.

Distributed by: Dechra Veterinary Products
7015 College Boulevard, Suite 525
Overland Park, KS 66211 866-933-2472
© 2016 Dechra Ltd. OSPHOS is a registered
trademark of Dechra Ltd. All rights reserved.
NADA 141-427, Approved by FDA


http://www.osphos.com http://www.dechra-us.com

Table of Contents for the Digital Edition of 2018 AGDF Program

Table of Contents
2018 AGDF Program - Cover1
2018 AGDF Program - Cover2
2018 AGDF Program - 1
2018 AGDF Program - 2
2018 AGDF Program - 3
2018 AGDF Program - Table of Contents
2018 AGDF Program - 5
2018 AGDF Program - 6
2018 AGDF Program - 7
2018 AGDF Program - 8
2018 AGDF Program - 9
2018 AGDF Program - 10
2018 AGDF Program - 11
2018 AGDF Program - 12
2018 AGDF Program - 13
2018 AGDF Program - 14
2018 AGDF Program - 15
2018 AGDF Program - 16
2018 AGDF Program - 17
2018 AGDF Program - 18
2018 AGDF Program - 19
2018 AGDF Program - 20
2018 AGDF Program - 21
2018 AGDF Program - 22
2018 AGDF Program - 23
2018 AGDF Program - 24
2018 AGDF Program - 25
2018 AGDF Program - 26
2018 AGDF Program - 27
2018 AGDF Program - 28
2018 AGDF Program - 29
2018 AGDF Program - 30
2018 AGDF Program - 31
2018 AGDF Program - 32
2018 AGDF Program - 33
2018 AGDF Program - 34
2018 AGDF Program - 35
2018 AGDF Program - 36
2018 AGDF Program - 37
2018 AGDF Program - 38
2018 AGDF Program - 39
2018 AGDF Program - 40
2018 AGDF Program - 41
2018 AGDF Program - 42
2018 AGDF Program - 43
2018 AGDF Program - 44
2018 AGDF Program - 45
2018 AGDF Program - 46
2018 AGDF Program - 47
2018 AGDF Program - 48
2018 AGDF Program - 49
2018 AGDF Program - 50
2018 AGDF Program - 51
2018 AGDF Program - 52
2018 AGDF Program - 53
2018 AGDF Program - 54
2018 AGDF Program - 55
2018 AGDF Program - 56
2018 AGDF Program - 57
2018 AGDF Program - 58
2018 AGDF Program - 59
2018 AGDF Program - 60
2018 AGDF Program - 61
2018 AGDF Program - 62
2018 AGDF Program - 63
2018 AGDF Program - 64
2018 AGDF Program - 65
2018 AGDF Program - 66
2018 AGDF Program - 67
2018 AGDF Program - 68
2018 AGDF Program - 69
2018 AGDF Program - 70
2018 AGDF Program - 71
2018 AGDF Program - 72
2018 AGDF Program - 73
2018 AGDF Program - 74
2018 AGDF Program - 75
2018 AGDF Program - 76
2018 AGDF Program - 77
2018 AGDF Program - 78
2018 AGDF Program - 79
2018 AGDF Program - 80
2018 AGDF Program - 81
2018 AGDF Program - 82
2018 AGDF Program - 83
2018 AGDF Program - 84
2018 AGDF Program - 85
2018 AGDF Program - 86
2018 AGDF Program - 87
2018 AGDF Program - 88
2018 AGDF Program - 89
2018 AGDF Program - 90
2018 AGDF Program - 91
2018 AGDF Program - 92
2018 AGDF Program - 93
2018 AGDF Program - 94
2018 AGDF Program - 95
2018 AGDF Program - 96
2018 AGDF Program - 97
2018 AGDF Program - 98
2018 AGDF Program - 99
2018 AGDF Program - 100
2018 AGDF Program - 101
2018 AGDF Program - 102
2018 AGDF Program - 103
2018 AGDF Program - 104
2018 AGDF Program - 105
2018 AGDF Program - 106
2018 AGDF Program - 107
2018 AGDF Program - 108
2018 AGDF Program - 109
2018 AGDF Program - 110
2018 AGDF Program - 111
2018 AGDF Program - 112
2018 AGDF Program - 113
2018 AGDF Program - 114
2018 AGDF Program - 115
2018 AGDF Program - 116
2018 AGDF Program - 117
2018 AGDF Program - 118
2018 AGDF Program - 119
2018 AGDF Program - 120
2018 AGDF Program - 121
2018 AGDF Program - 122
2018 AGDF Program - 123
2018 AGDF Program - 124
2018 AGDF Program - Cover3
2018 AGDF Program - Cover4
http://www.nxtbookMEDIA.com